Lee S. Schwartzberg MD, FACPChief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, Nevada
Dr. Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He did his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent three decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of hematology/oncology and Professor of Medicine at the University of Tennessee Health Science center from 2012-2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees including breast cancer.
Dr. Schwartzberg has published nearly 300 peer reviewed manuscripts, book chapters and monographs. He is founding editor in chief of the Elsevier website PracticeUpdate Oncology and founding editor in chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine and patient reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
State University of New York, BA and MS
New York Medical College, MD, FACP
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
He is a consultant for Amgen, Pfizer, Helsinn, Genentech, BMS, Myriad, AstraZeneca, Spectrum, and Napo.
He is also on the advisory board for Genomic Health Research Funding (Institution): Amgen and DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Febrile Neutropenia Risk With TCH(P) in HER2+ Breast Cancer
- Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer
- ESR1 Mutations and Therapeutic Resistance in Metastatic Breast Cancer
- BMI and Risk of Second Cancer Among Women With Breast Cancer
- Antibody Drug Conjugates of Trastuzumab for HER2+ MBC
- Pembrolizumab With Chemotherapy for TNBC
- Induction Dose Escalation of Everolimus in MBC
- CDK 4/6 Inhibitor as First-Line Therapy for Advanced Breast Cancer
- Addition of Everolimus to First-Line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
- Prognostic Utility of the Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma